Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer/Centerpulse Merger Would Build Minimally-Invasive Surgery Portfolio

This article was originally published in The Gray Sheet

Executive Summary

Centerpulse's allogenic bone concentrate (ABC) would give Zimmer a spine fusion product to compete directly with Medtronic Sofamor Danek's InFuse bone graft/LT-CAGE lumbar tapered fusion device

You may also be interested in...



Zimmer Rounds Out Spinal Offerings With Abbott Spine Acquisition

Zimmer's $360 million acquisition of Abbott's spinal surgery business will add pedicle screws and an interspinous stabilizer system to help round out Zimmer's own spinal offerings and create "critical mass" in the spinal business, the company says

Zimmer Rounds Out Spinal Offerings With Abbott Spine Acquisition

Zimmer's $360 million acquisition of Abbott's spinal surgery business will add pedicle screws and an interspinous stabilizer system to help round out Zimmer's own spinal offerings and create "critical mass" in the spinal business, the company says

Zimmer’s Endius Purchase Is “Part One” Of Spinal Device Acquisition Plan

Zimmer's purchase of minimally invasive spinal surgery system maker Endius fills a key gap in the firm's spinal portfolio and represents a first step in a broader spinal acquisition strategy, Zimmer says

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel